Precision System Science Co., Ltd.
Presentation Materials on Business Plan and Growth Potential
Explains the PSS platform business model centered on the company's nucleic acid extraction instruments. Proposes a policy to expand recurring revenue by combining ODM and own-brand sales centered on the magnetic-particle nucleic acid extraction technology "Magtration@". Describes the market outlook for magnetic-particle nucleic acid extraction kits and applications such as IgA nephropathy testing.
Key Figures
- Key Figure 1: PSS platform market share of approx. 5.8% as of 2024 (relative figure noted in the PDF)
- Key Figure 2: Overview of test demand for IgA nephropathy testing (background information such as the scale of dialysis patients in Japan)
- Key Figure 3: Description indicating the proportion of recurring revenue in the business model (revenue structure from the instrument × reagent × consumables platform)
AI要約
Business Structure and Platform Strategy
The PSS platform emphasizes recurring revenue from the combination of instrument × reagent × consumables, and plans global expansion through both own-brand sales and ODM. With Magtration@ technology at its core, the company highlights a one-stop model that realizes development to mass production of medical devices in a single flow by balancing ODM and own-brand sales. Major partners such as ELITech are cited, explaining a structure to expand into global markets via ODM.
Market Environment and Growth Opportunities
The market for magnetic-particle nucleic acid extraction kits is expected to continue growing post-COVID, and while the top five major players hold approximately 73.5% market share, PSS's current share is about 5.8% (as of 2024). The nucleic acid extraction market is expected to see efficiency improvements through full automation, and new clinical testing demand is anticipated from applications such as glycan analysis for IgA nephropathy testing.
Precision System Science Co., Ltd.
Company overview · Stock price · Financial data · All IR
